Goldline Pharmaceutical IPO
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 1.31x | 1.31x | 180.22x |
| NII | 18.07x | 108.19x | 1,662.35x |
| bNII > ₹10L | 24.46x | 146.48x | 1,662.35x |
| sNII 2-10L | 24.46x | 146.48x | 1,662.35x |
| Retail | 34.07x | 139.51x | 880.68x |
| Total | 20.79x | 93.19x | 840.57x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 |
| Expense | 19.45 | 21.04 | 24.20 |
| Profit (PAT) | 0.26 | 1.81 | 2.83 |
| Total Assets | 19.39 | 22.93 | 26.28 |
Peer Comparison
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 12.57 | 10 |
| Chandra Bhagat Pharma Limited | 1.14 | 37.73 | 3 |
Promoters & Holding Pattern
Promoters: Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
Strengths & Risks
- Heavily oversubscribed — 840.6x overall (so far).
- Strong institutional (QIB) demand — 180.2x.
- Revenue grew 19% in the latest reported year.
- Solid profit margin — 10.1%.
- Strong return on equity — 36%.
- Elevated leverage — debt/equity of 1.50.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
About Goldline Pharmaceutical
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy. The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Company Contact Information
Goldline Pharmaceutical Ltd., 103, F-1, Leela Apartment, Shilpa HSG Society,, Near Saptagiri Nagar, Shanidham,, Narendra Nagar,, Nagpur, Maharashtra, 440015
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Goldline Pharmaceutical IPO - Quick Take
Goldline Pharmaceutical has set a price band of Rs 41–Rs 43 per share for an issue size of Rs 12 crore. The stock listed with a 38.95% gain versus its issue price on May 19, 2026.
The issue is promoted by Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal with Cumulative Capital Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (Rs 9 crore) and general Corporate Purpose.
On fundamentals, the company is posting revenue growth of 19.1%, a profit margin of 10.1%, return on equity of 35.8% in its most recent reported period. Listed peers in this segment include Mono Pharmacare Limited (P/E 12.57x, market cap Rs 10 crore) and Chandra Bhagat Pharma Limited (P/E 37.73x, market cap Rs 3 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Frequently Asked Questions
Goldline Pharmaceutical IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed. Its last GMP before listing was 34.9%. Of the 32 SME IPOs we have tracked with a final GMP of 25% or more, 32 listed above, 0 flat and 0 below the issue price; Goldline Pharmaceutical listed 39% above its issue price.
See the full Goldline Pharmaceutical GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Goldline Pharmaceutical
No comments yet. Be the first to share your opinion!